Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community

Tune in to our upcoming broadcast to learn about the latest advances in chronic lymphocytic leukmia and small lymphocytic lymphoma. Register today!

 

SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
Related Articles
Ixazomib Improves PFS as Frontline Maintenance in Multiple Myeloma
Kumar Discusses Path Forward for Venetoclax in Myeloma
Melflufen Regimen Elicits Activity in Relapsed Myeloma With Extramedullary Disease
Related Videos
Dr. Chaudhry on Novel Treatment Regimens in Relapsed/Refractory Multiple Myeloma
Dr. Martin on Treating First Relapse in Multiple Myeloma
Dr. Chaudhry on DRd Triplet in Transplant-Ineligible Multiple Myeloma
News >

Venetoclax Active in Heavily Treated Multiple Myeloma

Published: Wednesday, Dec 21, 2016

Shaji Kumar, MD

Shaji Kumar, MD

The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma, according to results of a phase I clinical trial presented at the 2016 ASH Annual Meeting.1

 

References

  1. Kumar S, Vij R, Kaufman JL, et al. Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I study. Presented at: 58th ASH Annual Meeting and Exposition; December 3-6, 2016; San Diego, CA. Abstract 488.
  2. Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28:210-212.
  3. Punnoose EA, Leverson JD, Peale F. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15:1132-1144.

... to read the full story
To Read the Full Story
REGISTER
LOG IN

View Other News on Multiple Myeloma
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
 
x